Neurocrine Biosciences Says Treatment Can Alleviate Several Symptoms Associated With Depressive Disorder
Portfolio Pulse from Vandana Singh
Neurocrine Biosciences Inc (NASDAQ:NBIX) announced positive Phase 2 results for NBI-1065845, a treatment for major depressive disorder (MDD), developed in collaboration with Takeda Pharmaceutical Company Limited (NYSE:TAK). The study met its primary and key secondary endpoints, showing significant improvement in depression scores. The treatment was well tolerated, with headache being the most common adverse event. William Blair maintains an Outperform rating on Neurocrine, highlighting the potential for significant sales and the importance of Ingrezza revenue.
April 23, 2024 | 5:28 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Neurocrine Biosciences announced positive results from the Phase 2 study of NBI-1065845 for treating MDD, developed in collaboration with Takeda. The treatment's success and potential sales opportunity exceeding $1 billion are highlighted, alongside the importance of Ingrezza revenue.
The positive outcome of the Phase 2 study for NBI-1065845 in treating MDD, a collaboration with Takeda, indicates a significant potential for market success. The anticipation of high sales opportunities and the emphasis on Ingrezza revenue contribute to a positive outlook for NBIX's stock in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100
POSITIVE IMPACT
Takeda Pharmaceutical Company Limited is in a strategic collaboration with Neurocrine Biosciences for the development and commercialization of NBI-1065845, a treatment for MDD. The positive Phase 2 results could enhance Takeda's psychiatry pipeline.
Takeda's collaboration with Neurocrine on the development of NBI-1065845 for MDD treatment and the positive Phase 2 results could significantly impact Takeda's psychiatry pipeline, potentially leading to increased interest in TAK's stock in the short term.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 80